Developer docs
API playgroundTry for free, no card

Search company profiles

First Ascent Biomedical

Full company profile

uuid0000rh7

Namestring
First Ascent Biomedical
Legal namestring
First Ascent Biomedical Inc.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

First Ascent Biomedical is a clinical-stage biotechnology company founded in 2018 and headquartered in Miami, Florida, that has developed a Functional Precision Medicine (FPM) platform branded as xDRIVE — the Ex Vivo Drug Response Identification & Validation Engine. The platform combines patient-derived live-cell testing of 150+ FDA-approved therapies and combinations, DNA/RNA genomic sequencing, and AI cancer weakness mapping to deliver personalized cancer treatment recommendations in an average of 10 days. The company's evidence base is anchored by a peer-reviewed Nature Medicine study showing 83% of patients respond better to FPO-guided therapy versus standard of care and 8.5x longer progression-free survival, with the platform clinically validated across 52 cancer types.

The company operates two CLIA-certified laboratories in Miami (the first opened January 2025, the second in September 2025) and is developing two additional CLIA-approved labs at Gannon University's I-HACK facility in Erie, Pennsylvania, targeted for completion in fall 2026. Its customer base spans three segments: oncologists and cancer treatment centers (xDrive), individual cancer patients and caregivers, and biopharmaceutical companies (DxPP for drug development, biomarker discovery, and target identification). Named pharma partners include Roche, GSK, Blueprint Medicines, Prelude Therapeutics, Galera Therapeutics, and MorphoSys, with academic collaborations at institutions such as Florida International University, Johns Hopkins, Stanford, UCLA, UCSF, and Nicklaus Children's Hospital.

The business model is hybrid: clinical testing services to physicians and patients (currently largely subsidized through grants and sponsorships including the $2M Florida Cancer Innovation Fund grant and $350K Fight Colorectal Cancer Foundation grant), plus professional services and a stated licensing/royalty pathway to pharma via the DxPP platform, with FDA Breakthrough Device Designation targeted as part of a three-year commercialization pathway. Total disclosed equity capital is approximately $6.58M (a 2021 round of $580K and a 2025 seed of $6M), augmented by ~$6.5M in non-dilutive grant funding. The company is pursuing Series A financing to scale.

Short descriptiontext

First Ascent Biomedical is a clinical-stage biotech that uses AI-driven functional precision medicine — combining live-cell drug testing of 150+ therapies, genomic sequencing, and machine learning — to deliver personalized cancer treatment recommendations in roughly 10 days for oncologists, patients, and biopharma partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMiami, United States
HQ citystring
Miami
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
functional precision medicine, personalized cancer treatment, ex vivo drug response testing, AI oncology platform, biomarker discovery services
Industry6 codes
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAANAI
Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code3 codes
  • Medical and Diagnostic Laboratories62151
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Precision Oncology Services
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical Testing Services
TypeSubscription Recurring
Description

Provides patient-specific drug sensitivity testing through CLIA-certified laboratories, generating actionable treatment reports for oncologists. Free testing offered to eligible patients through sponsorships and grants.

firstascentbiomedical.com
2Pharmaceutical Drug Development Services
TypeProfessional Services
Description

Offers pharmaceutical companies biomarker discovery, target identification, and drug development support using the platform's functional testing and AI capabilities.

firstascentbiomedical.com
3DxPP (Drug Response Prediction Platform)
TypeLicensing Royalties
Description

Delivers critical insights for pharma and biotech to shorten early-stage drug development timelines and reduce investment, positioning for commercialization through FDA Breakthrough Device Designation pathway.

finance.yahoo.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Free testing for eligible Florida residents
ModelOtherBilling cadencePay-as-you-go
Notes

Free testing available to eligible Florida residents and colorectal cancer patients nationwide through sponsorships.

prnewswire.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 2 records shown
1xDRIVE (Ex Vivo Drug Response Identification & Validation Engine)
Description

Oncology decision support system combining functional drug validation, genomic sequencing, and AI cancer weakness mapping to provide patient-specific treatment recommendations.

firstascentbiomedical.com
+1 more record
Core offering1 text field

First Ascent Biomedical delivers personalized cancer treatment recommendations through its xDRIVE Functional Precision Medicine platform, which combines patient-derived live-cell drug sensitivity testing (against 150+ FDA-approved therapies and combinations), DNA/RNA genomic sequencing, and AI cancer weakness mapping. Services are delivered through CLIA-certified laboratories to oncologists, cancer patients, and biopharma partners, with treatment insights returned in approximately 10 days.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 83% of patients respond better to FPO-guided therapy compared to doctors' choice or standard of care
+3 more records
Product overview1 text field

First Ascent Biomedical offers the xDRIVE platform—a unified Functional Precision Medicine system comprising two integrated applications: xDrive for patients and oncologists, and DxPP for pharmaceutical and biotech companies. The platform combines functional drug validation (live tumor cell testing against 150+ FDA-approved therapies), genomic sequencing (DNA/RNA analysis), and AI-driven cancer weakness mapping to deliver personalized treatment recommendations in approximately 10 days. The company operates as a CLIA-certified clinical-stage biotech providing both direct clinical decision support services and drug development partnership programs.

Product and service4 records
1xDRIVE Functional Precision Medicine Platform
CategoryPrecision Oncology Platform
Description

First-in-kind oncology decision support platform combining functional drug validation (live-cell testing of 150+ FDA-approved therapies and combinations), DNA/RNA genomic sequencing, and AI cancer weakness mapping to deliver patient-specific treatment recommendations for solid and liquid cancers in approximately 10 days.

2xDrive Patient and Oncologist Application
CategoryClinical Decision Support Application
Description

Patient- and oncologist-facing application that delivers evidence of how an individual tumor responds to FDA-approved drugs in approximately 10 days, enabling faster, more effective personalized care for patients who have exhausted standard treatment options.

3DxPP (Drug Prediction Platform) for Pharma and Biotech
CategoryDrug Development Services Platform
Description

Pharmaceutical and biotech-facing drug sensitivity testing and causal machine learning platform that delivers critical insights to shorten early-stage drug development timelines, reduce investment, and support biomarker discovery and target identification for biopharma partners.

4Functional Precision Medicine Clinical Testing Services
CategoryClinical Laboratory Testing Services
Description

CLIA-certified laboratory services that screen patient-derived live tumor cells against 150+ FDA-approved therapies and combinations in parallel, generating personalized drug sensitivity reports delivered to oncologists in approximately 10 days.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Collaboration to develop two new laboratories in Gannon's I-HACK building in Erie, PA. First Ascent will occupy 3,000 sq ft of lab space and 2,000 sq ft for offices, expected to handle 20,000 patients annually. Project total cost $6.5 million.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Partnership to establish 3,000 sq ft laboratory in Gannon's I-HACK to augment existing lab and expand medical laboratory science program.

3Nicklaus Children's Hospital
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Pediatric hospital where Logan received treatment, integrating personalized FPM findings into real-world pediatric cancer care.

firstascentbiomedical.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner providing scientific leadership; research conducted in FIU's cutting-edge translational oncology labs where technology was developed by co-founder Dr. Diana Azzam.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Selected into CancerX 2025 Driving Innovation in Oncology Cohort. CancerX is a groundbreaking public-private partnership designed to accelerate innovation in oncology.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Pharmaceutical partner collaborating with First Ascent for drug development and biomarker identification services.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Pharmaceutical partner for drug development and biomarker discovery using functional precision medicine platform.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Pharmaceutical partner for targeted therapy development and biomarker identification.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Pharmaceutical partner for cancer drug development using functional testing platform.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Biopharmaceutical partner for cancer therapy development.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Pharmaceutical partner for oncology drug development.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Partner in combining engineering and biology to more effectively drive informed decisions for pharmaceutical companies, reducing time and costs in drug development.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Tempus AI
TypeDirect peer
Description

AI-driven precision medicine platform offering genomic sequencing and clinical decision support for oncologists. Closest comparable to xDRIVE's combination of molecular profiling, AI analytics, and oncology clinical workflow integration, though with deeper genomic focus rather than functional live-cell testing.

TypeBroad incumbent
Description

Roche subsidiary providing comprehensive genomic profiling for solid tumors and hematologic malignancies. Established market leader in oncology molecular testing with extensive reimbursement, directly competing for oncologist mindshare and clinical decision support workflows.

TypeDirect peer
Description

Molecular profiling company offering DNA/RNA sequencing plus AI-driven precision oncology insights for treatment selection. Comparable in combining multi-omic data with clinical decision support, and serves similar biopharma partners for biomarker discovery.

TypeBroad incumbent
Description

Liquid biopsy and precision oncology company with established commercial labs and FDA-approved tests. Relevant peer for CLIA lab operations and oncology testing infrastructure, though focused on blood-based rather than functional cell-based approaches.

TypeEmerging player
Description

Cancer genomics company offering tumor profiling and ctDNA testing for oncology treatment selection and pharma clinical trial support. Comparable in serving both clinical oncology and biopharma drug development customers.

TypeDirect peer
Description

Precision oncology platform providing molecular profiling and treatment recommendations for advanced cancer patients. Comparable business model combining clinical testing with pharma services for trial enrollment and biomarker discovery.

TypeEmerging player
Description

Liquid biopsy and precision oncology company (acquired by Agilent) focused on next-generation sequencing-based oncology testing. Comparable as a clinical oncology diagnostics platform serving pharma and clinical customers.

TypeEmerging player
Description

AI-driven oncology drug development company using machine learning to accelerate cancer therapy development. Comparable in combining AI/ML with oncology drug development, though focused on proprietary drug pipeline rather than diagnostic services.

9Notable Labs
TypeDirect peer
Description

Functional precision medicine company using ex vivo drug sensitivity testing to predict patient response to cancer therapies. Direct comparable in the functional/live-cell testing approach for personalized oncology treatment selection.

TypeDirect peer
Description

Oncology platform offering patient-derived xenograft (PDX) and ex vivo drug sensitivity testing services for pharma and clinical applications. Comparable in functional precision medicine testing model serving both clinical and biopharma customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

First Ascent Biomedical

Precision Oncology Servicesfirstascentbiomedical.com

First Ascent Biomedical is a clinical-stage biotech that uses AI-driven functional precision medicine — combining live-cell drug testing of 150+ therapies, genomic sequencing, and machine learning — to deliver personalized cancer treatment recommendations in roughly 10 days for oncologists, patients, and biopharma partners.

What First Ascent Biomedical does

First Ascent Biomedical is a clinical-stage biotechnology company founded in 2018 and headquartered in Miami, Florida, that has developed a Functional Precision Medicine (FPM) platform branded as xDRIVE — the Ex Vivo Drug Response Identification & Validation Engine. The platform combines patient-derived live-cell testing of 150+ FDA-approved therapies and combinations, DNA/RNA genomic sequencing, and AI cancer weakness mapping to deliver personalized cancer treatment recommendations in an average of 10 days. The company's evidence base is anchored by a peer-reviewed Nature Medicine study showing 83% of patients respond better to FPO-guided therapy versus standard of care and 8.5x longer progression-free survival, with the platform clinically validated across 52 cancer types.

The company operates two CLIA-certified laboratories in Miami (the first opened January 2025, the second in September 2025) and is developing two additional CLIA-approved labs at Gannon University's I-HACK facility in Erie, Pennsylvania, targeted for completion in fall 2026. Its customer base spans three segments: oncologists and cancer treatment centers (xDrive), individual cancer patients and caregivers, and biopharmaceutical companies (DxPP for drug development, biomarker discovery, and target identification). Named pharma partners include Roche, GSK, Blueprint Medicines, Prelude Therapeutics, Galera Therapeutics, and MorphoSys, with academic collaborations at institutions such as Florida International University, Johns Hopkins, Stanford, UCLA, UCSF, and Nicklaus Children's Hospital.

The business model is hybrid: clinical testing services to physicians and patients (currently largely subsidized through grants and sponsorships including the $2M Florida Cancer Innovation Fund grant and $350K Fight Colorectal Cancer Foundation grant), plus professional services and a stated licensing/royalty pathway to pharma via the DxPP platform, with FDA Breakthrough Device Designation targeted as part of a three-year commercialization pathway. Total disclosed equity capital is approximately $6.58M (a 2021 round of $580K and a 2025 seed of $6M), augmented by ~$6.5M in non-dilutive grant funding. The company is pursuing Series A financing to scale.

First Ascent Biomedical firmographics

Firmographics
Name
First Ascent Biomedical
Legal name
First Ascent Biomedical Inc.
Website
https://firstascentbiomedical.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
First Ascent Biomedical is a clinical-stage biotech that uses AI-driven functional precision medicine — combining live-cell drug testing of 150+ therapies, genomic sequencing, and machine learning — to deliver personalized cancer treatment recommendations in roughly 10 days for oncologists, patients, and biopharma partners.
Ownership category
akta.pro rank

First Ascent Biomedical industry classification

Industry
Product category
Precision Oncology Services
NAICS
Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAANAI
Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Functional precision medicine
  • Personalized cancer treatment
  • Ex vivo drug response testing
  • AI oncology platform
  • Biomarker discovery services

Where First Ascent Biomedical is headquartered

Location

Headquarters

HQ city
Miami
HQ country
United States
HQ region
North America

Offices3 records

Markets served

First Ascent Biomedical business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Clinical Testing Services: Provides patient-specific drug sensitivity testing through CLIA-certified laboratories, generating actionable treatment reports for oncologists. Free testing offered to eligible patients through sponsorships and grants.
  2. Pharmaceutical Drug Development Services: Offers pharmaceutical companies biomarker discovery, target identification, and drug development support using the platform's functional testing and AI capabilities.
  3. DxPP (Drug Response Prediction Platform): Delivers critical insights for pharma and biotech to shorten early-stage drug development timelines and reduce investment, positioning for commercialization through FDA Breakthrough Device Designation pathway.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goFree testing for eligible Florida residents

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

First Ascent Biomedical product offering

Product offering

Core offering

First Ascent Biomedical delivers personalized cancer treatment recommendations through its xDRIVE Functional Precision Medicine platform, which combines patient-derived live-cell drug sensitivity testing (against 150+ FDA-approved therapies and combinations), DNA/RNA genomic sequencing, and AI cancer weakness mapping. Services are delivered through CLIA-certified laboratories to oncologists, cancer patients, and biopharma partners, with treatment insights returned in approximately 10 days.

Product overview

First Ascent Biomedical offers the xDRIVE platform—a unified Functional Precision Medicine system comprising two integrated applications: xDrive for patients and oncologists, and DxPP for pharmaceutical and biotech companies. The platform combines functional drug validation (live tumor cell testing against 150+ FDA-approved therapies), genomic sequencing (DNA/RNA analysis), and AI-driven cancer weakness mapping to deliver personalized treatment recommendations in approximately 10 days. The company operates as a CLIA-certified clinical-stage biotech providing both direct clinical decision support services and drug development partnership programs.

Differentiator

Problem solved

Functional benefit

Brands

  • xDRIVE (Ex Vivo Drug Response Identification & Validation Engine): Oncology decision support system combining functional drug validation, genomic sequencing, and AI cancer weakness mapping to provide patient-specific treatment recommendations.
  • DxPP

Products and services

  • xDRIVE Functional Precision Medicine Platform First-in-kind oncology decision support platform combining functional drug validation (live-cell testing of 150+ FDA-approved therapies and combinations), DNA/RNA genomic sequencing, and AI cancer weakness mapping to deliver patient-specific treatment recommendations for solid and liquid cancers in approximately 10 days.
  • xDrive Patient and Oncologist Application Patient- and oncologist-facing application that delivers evidence of how an individual tumor responds to FDA-approved drugs in approximately 10 days, enabling faster, more effective personalized care for patients who have exhausted standard treatment options.
  • DxPP (Drug Prediction Platform) for Pharma and Biotech Pharmaceutical and biotech-facing drug sensitivity testing and causal machine learning platform that delivers critical insights to shorten early-stage drug development timelines, reduce investment, and support biomarker discovery and target identification for biopharma partners.
  • Functional Precision Medicine Clinical Testing Services CLIA-certified laboratory services that screen patient-derived live tumor cells against 150+ FDA-approved therapies and combinations in parallel, generating personalized drug sensitivity reports delivered to oncologists in approximately 10 days.

Quantifiable outcome

  • 83% of patients respond better to FPO-guided therapy compared to doctors' choice or standard of care
  • +3 more outcomes

Companies that use First Ascent Biomedical

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

First Ascent Biomedical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

First Ascent Biomedical partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered flagship, major and core.

  • Gannon UniversityflagshipStrategic or Co-development PartnerCollaboration to develop two new laboratories in Gannon's I-HACK building in Erie, PA. First Ascent will occupy 3,000 sq ft of lab space and 2,000 sq ft for offices, expected to handle 20,000 patients annually. Project total cost $6.5 million.
  • Saint Vincent Hospital (AHN Cancer Institute)flagshipStrategic or Co-development PartnerPartnership to establish 3,000 sq ft laboratory in Gannon's I-HACK to augment existing lab and expand medical laboratory science program.
  • Nicklaus Children's HospitalmajorStrategic or Co-development PartnerPediatric hospital where Logan received treatment, integrating personalized FPM findings into real-world pediatric cancer care.
  • Florida International University (FIU)coreStrategic or Co-development PartnerAcademic partner providing scientific leadership; research conducted in FIU's cutting-edge translational oncology labs where technology was developed by co-founder Dr. Diana Azzam.
  • CancerXmajorStrategic or Co-development PartnerSelected into CancerX 2025 Driving Innovation in Oncology Cohort. CancerX is a groundbreaking public-private partnership designed to accelerate innovation in oncology.
  • RochemajorStrategic or Co-development PartnerPharmaceutical partner collaborating with First Ascent for drug development and biomarker identification services.
  • GSKmajorStrategic or Co-development PartnerPharmaceutical partner for drug development and biomarker discovery using functional precision medicine platform.
  • Blueprint MedicinesmajorStrategic or Co-development PartnerPharmaceutical partner for targeted therapy development and biomarker identification.
  • Prelude TherapeuticsmajorStrategic or Co-development PartnerPharmaceutical partner for cancer drug development using functional testing platform.
  • Galera TherapeuticsmajorStrategic or Co-development PartnerBiopharmaceutical partner for cancer therapy development.
  • MorphoSysmajorStrategic or Co-development PartnerPharmaceutical partner for oncology drug development.
  • Children's Cancer Therapy Development InstitutemajorStrategic or Co-development PartnerPartner in combining engineering and biology to more effectively drive informed decisions for pharmaceutical companies, reducing time and costs in drug development.

Scale indicators12 records

Recent moves9 records

Expansion highlights6 records

First Ascent Biomedical competitors and assessment

Company assessment

Direct peers

  • Tempus AI: AI-driven precision medicine platform offering genomic sequencing and clinical decision support for oncologists. Closest comparable to xDRIVE's combination of molecular profiling, AI analytics, and oncology clinical workflow integration, though with deeper genomic focus rather than functional live-cell testing.
  • Caris Life Sciences: Molecular profiling company offering DNA/RNA sequencing plus AI-driven precision oncology insights for treatment selection. Comparable in combining multi-omic data with clinical decision support, and serves similar biopharma partners for biomarker discovery.
  • Strata Oncology: Precision oncology platform providing molecular profiling and treatment recommendations for advanced cancer patients. Comparable business model combining clinical testing with pharma services for trial enrollment and biomarker discovery.
  • Notable Labs: Functional precision medicine company using ex vivo drug sensitivity testing to predict patient response to cancer therapies. Direct comparable in the functional/live-cell testing approach for personalized oncology treatment selection.
  • Champions Oncology: Oncology platform offering patient-derived xenograft (PDX) and ex vivo drug sensitivity testing services for pharma and clinical applications. Comparable in functional precision medicine testing model serving both clinical and biopharma customers.

Broad incumbents

  • Foundation Medicine: Roche subsidiary providing comprehensive genomic profiling for solid tumors and hematologic malignancies. Established market leader in oncology molecular testing with extensive reimbursement, directly competing for oncologist mindshare and clinical decision support workflows.
  • Guardant Health: Liquid biopsy and precision oncology company with established commercial labs and FDA-approved tests. Relevant peer for CLIA lab operations and oncology testing infrastructure, though focused on blood-based rather than functional cell-based approaches.

Emerging players

  • Personalis: Cancer genomics company offering tumor profiling and ctDNA testing for oncology treatment selection and pharma clinical trial support. Comparable in serving both clinical oncology and biopharma drug development customers.
  • Resolution Bioscience: Liquid biopsy and precision oncology company (acquired by Agilent) focused on next-generation sequencing-based oncology testing. Comparable as a clinical oncology diagnostics platform serving pharma and clinical customers.
  • Lantern Pharma: AI-driven oncology drug development company using machine learning to accelerate cancer therapy development. Comparable in combining AI/ML with oncology drug development, though focused on proprietary drug pipeline rather than diagnostic services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

First Ascent Biomedical social profiles

Digital presence

First Ascent Biomedical compliance and trust

Trust signal

Compliance1 record

First Ascent Biomedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

First Ascent Biomedical leadership team

Management profile

Number of profiles

Profiles6 records

First Ascent Biomedical funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

First Ascent Biomedical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about First Ascent Biomedical

What does First Ascent Biomedical do?

First Ascent Biomedical delivers personalized cancer treatment recommendations through its xDRIVE Functional Precision Medicine platform, which combines patient-derived live-cell drug sensitivity testing (against 150+ FDA-approved therapies and combinations), DNA/RNA genomic sequencing, and AI cancer weakness mapping. Services are delivered through CLIA-certified laboratories to oncologists, cancer patients, and biopharma partners, with treatment insights returned in approximately 10 days.

Is First Ascent Biomedical a public or private company?

First Ascent Biomedical is a private company. It is classified as venture growth investor backed and is currently operating.

When was First Ascent Biomedical founded?

First Ascent Biomedical was founded in 2018. It employs 11 to 50 people.

Where is First Ascent Biomedical based?

First Ascent Biomedical is headquartered in Miami, United States, in the North America region.

How does First Ascent Biomedical make money?

Three revenue lines are on record. Clinical Testing Services are the primary driver. The others are pharmaceutical Drug Development Services and dxPP (Drug Response Prediction Platform).

Who are First Ascent Biomedical's main competitors?

Direct peers on record are Tempus AI, Caris Life Sciences, Strata Oncology, Notable Labs and Champions Oncology. Broad incumbents are Foundation Medicine and Guardant Health. Emerging players are Personalis, Resolution Bioscience and Lantern Pharma.

Does First Ascent Biomedical have an API?

No public API is recorded for First Ascent Biomedical.

What industry is First Ascent Biomedical in?

First Ascent Biomedical's product category is Precision Oncology Services. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLAAANAD, Molecular Tumor Boards & Clinical Interpretation Services. Its NAICS code is 62151 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireRaymond Rodriguez-Torres Appointed First Ascent Biomedical New President to Scale Functional Precision OncologyFirst Ascent Biomedical appointed Raymond Rodriguez-Torres as President to lead scaling of its Functional Precision Oncology platform and expand access to its xDRIVE decision-support system. Rodriguez-Torres brings over two decades of biotech leadership experience from Genentech, Roche, and Sanofi-Aventis, with a personal mission rooted in childhood cancer advocacy following his daughter Bella's legacy. Among his first priorities, he will focus on broadening Series A funding initiatives and engaging strategic partners to accelerate market adoption of the platform, which has been clinically validated across 52 cancer types.PR NewswireThe Lab Catches Up to the Clinic: How Functional Precision Oncology Goes Beyond GenomicsFirst Ascent Biomedical has developed Functional Precision Oncology (FPO), a live tumor cell testing platform that generates actionable treatment insights in approximately 10 days, bridging the gap between genomic testing and clinical outcomes in cancer care. A prospective clinical study published in Nature Medicine demonstrated that 83% of patients responded better to FPO-guided therapy and remained cancer-free 8.5 times longer compared to their previous treatments. The platform preserves the tumor microenvironment and cellular heterogeneity to more accurately predict real-world treatment responses, offering clinicians a validated tool for personalizing cancer therapy decisions.TalkerieMedical labs begin to take shape in Gannon’s I-HACKConstruction has begun on biomedical laboratories at Gannon University's Institute for Health and Cyber Knowledge (I-HACK) in Erie, Pennsylvania, marking the transition from planning to full construction on a collaborative project designed to expand cancer research and address a regional workforce shortage. The $6.5 million project, expected to be completed this fall, brings together Gannon University, First Ascent Biomedical, AHN Saint Vincent Hospital, and Allegheny Health Network to establish two new labs and related medical facilities. First Ascent Biomedical's expansion will include a 3,000-square-foot CLIA-approved laboratory to process up to 20,000 patients annually and create 38 jobs immediately, with growth projected to exceed 100 jobs within five years.PR NewswireFirst Ascent Biomedical Opens FPM Cancer Lab in Miami; Welcomes World-Class Clinical LeadershipFirst Ascent Biomedical has officially opened a CLIA and CAP-certified Functional Precision Medicine (FPM) laboratory in Miami, now accepting patient samples through physician referrals for personalized cancer treatment testing. The lab tests hundreds of FDA-approved drugs against patient-derived live tumor cells and delivers results in approximately 10 days. The company has also added two clinical leaders—Dr. Maggie Fader as Chief Medical Officer and Dr. Prasanth Reddy to the Medical Advisory Board—and is offering sponsored free testing for 200 eligible Florida residents and colorectal cancer patients nationwide.PR NewswireBehind the Relapse No One Saw Coming: How First Ascent Biomedical Is Changing Cancer Treatment DecisionsFirst Ascent Biomedical unveiled its Functional Precision Medicine platform through the case of Logan Jenner, a five-year-old with acute myeloid leukemia who achieved remission after the platform identified a personalized drug combination when conventional treatments failed. A study published in Nature Medicine found that 83% of patients in First Ascent's trials experienced improved outcomes, remaining cancer-free for a median of 8.5 times longer than with previous treatments. The platform combines patient-derived live-cell testing, genomics, and AI to deliver personalized treatment reports to oncologists in an average of 10 days.Bio-itworldRethinking Precision Oncology in the Age of Functional DataJim Foote, CEO of First Ascent Biomedical, advocates for Functional Precision Medicine (FPM) as a superior alternative to standard oncology care by testing live tumor cells against drugs combined with AI. This approach aims to replace population-based averages with individualized treatment plans that provide faster, evidence-based results for patients.PR NewswireExposing the Deadly Guesswork in Cancer Care: JOTO PR Signs First Ascent BiomedicalJOTO PR Disruptors has signed First Ascent Biomedical as a client to amplify its AI-driven precision medicine technology for cancer treatment. First Ascent Biomedical tests patients' live cancer cells against FDA-approved drugs to provide personalized treatment insights in approximately ten days. The company claims its approach has demonstrated an 83% improvement in patient response rates and helped patients remain cancer-free 8.5 times longer compared to previous therapies.PR NewswirePersonalized Cancer Insights, Grounded in Biology, DNA/RNA & AI Delivered in an Average of 10 DaysFirst Ascent Biomedical has launched a Functional Precision Medicine platform that tests live cancer cells against FDA-approved drugs and combinations, delivering personalized treatment recommendations in an average of 10 days. The platform combines functional drug validation, DNA/RNA sequencing, and AI analysis, with clinical data showing 83% of patients responded better to FPM-identified treatments and remained cancer-free 8.5 times longer compared to previous therapies. The company, headquartered in Miami, positions its CLIA-certified platform as a complement to genomics rather than a replacement, aiming to help oncologists make faster, evidence-based treatment decisions.PR NewswireDisruption in Cancer Care: How Jim Foote' AI is Revolutionizing OncologyFirst Ascent Biomedical CEO Jim Foote discussed the company's AI-driven functional precision medicine platform that tests up to 152 FDA-approved drugs directly on a patient's live tumor cells to identify the most effective personalized cancer treatments. The platform combines functional drug testing, multi-omics sequencing, and AI analysis to provide oncologists with ranked lists of effective treatments, moving away from the standard "one-size-fits-all" approach that currently fails one-third of cancer patients. This technology represents a convergence of AI, robotics, and advanced drug testing aimed at making personalized cancer treatment more accessible and effective.